Skip to main content

Advertisement

Table 2 Medication taken at enrollment

From: Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort

Medication Number (%) Mean dose (SD) Dose range
Prednisolone 1430 (77.46 %) 11.08 mg (12.78) 0.50–200 mg
Antimalarial 1333 (72.21 %) 291.19 mg (104.56)a 28.57–600 mga
Methotrexate 75 (4.06 %) 13.79 mg (6.73) 2.50–50 mg
Azathioprine 412 (22.32 %) 73.99 mg (30.29) 12.50–200 mg
Mycophenolate mofetil 306 (16.58 %) 1247.70 mg (546.96) 50–3000 mg
Mycophenolic acid 41 (2.22 %) 1102.93 mg (645.86) 180–2160 mg
Leflunomide 38 (2.06 %) 15.53 mg (5.49) 10–30 mg
Cyclosporine 35 (1.90 %) 126.43 mg (65.29) 50–300 mg
Cyclophosphomideb 73 (3.95 %) N/A N/A
Rituximabb 13 (0.70 %) N/A N/A
Belimumabb 15 (0.81 %) N/A N/A
Any Immunosuppressantc 940 (50.92 %) N/A N/A
  1. aBased on hydroxychloroquine dosing - Indonesia and Thailand predominantly use chloroquine. bTaken in the last 6 months. cEither methotrexate, azathioprine, mycophenolate, leflunomide, cyclosporine, cyclophosphamide, rituximab and/or belimumab. Maximum recommended dose: hydroxychloroquine ≤400 mg; methotrexate ≤30 mg; azathioprine ≤200 mg; mycophenolate mofetil ≤3000 mg; mycophenolic acid ≤2160 mg; leflunomide ≤20 mg
  2. N/A - dosing not applicable